Patents by Inventor Hilde Revets

Hilde Revets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab)
    Patent number: 7893026
    Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: February 22, 2011
    Assignees: VIB VZW, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Rudi Beyaert, Hilde Revets, Lieven Huang
  • Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab)
    Publication number: 20090023650
    Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
    Type: Application
    Filed: April 11, 2006
    Publication date: January 22, 2009
    Inventors: Rudi Beyaert, Hilde Revets, Lieven Huang
  • Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells
    Publication number: 20080199472
    Abstract: The present invention reates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with the domain and repress the tumor invasiveness and/or the metastasis.
    Type: Application
    Filed: February 14, 2008
    Publication date: August 21, 2008
    Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Patrick De Baetselier, Nick Devoogdt, Gholamreza Hassanzadeh Ghassabeh
  • Immunoconjugates
    Publication number: 20070031430
    Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used for the preparation of a medicament to treat tumours.
    Type: Application
    Filed: October 4, 2006
    Publication date: February 8, 2007
    Applicants: Vlaams Interuniversitair Instituut, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Virna Cortez-Retamozo, Serge Muyldermans, Patrick De Baetselier
  • Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells
    Publication number: 20060111294
    Abstract: The present invention relates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with said domain and repress the tumor invasiveness and/or the metastasis.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 25, 2006
    Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Vrije Universiteit Brussel
    Inventors: Hilde Revets, Patrick De Baetselier, Nick Devoogdt, Gholamreza Hassanzadeh Ghassabeh
  • Th1 inducing natural adjuvant for heterologous antigens
    Patent number: 6936263
    Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 30, 2005
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Hilde Revets, Pierre Cornelis, Patrick De Baetselier
  • Immunoconjugates
    Publication number: 20050048060
    Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used, for example, for the preparation of a medicament to treat tumors.
    Type: Application
    Filed: July 6, 2004
    Publication date: March 3, 2005
    Inventors: Hilde Revets, Virna Cortez-Retamozo, Serge Muyldermans, Patrick De Baetselier
  • Th1 inducing natural adjuvant for heterologous antigens
    Publication number: 20030059439
    Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
    Type: Application
    Filed: August 16, 2002
    Publication date: March 27, 2003
    Inventors: Hilde Revets, Pierre Cornelis, Patrick De Baetselier